QGLY - Tech Talk, Innuendo, & Anything Goes Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QGLY - Tech Talk, Innuendo, & Anything Goes

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Louis Cornell who wrote (3)	10/5/1997 1:54:00 AM
From: shlama	of 53

<<The $30-35 target is based on the assumption that by the time the winter sales start to come in, the market will conservatively value next year's earnings at 20-22X $1.50 per share.>> I also agree with these numbers but I think that there many, many variables that will determine where this stock is in the spring. The results of the clinical study, winter sales #'s, international distribution, and competition(or lack thereof) will be the determining factors of stock price in the spring....and if these are all postive than Mr. Lawson's #'s are probably right on target. This all IMHO. shlama

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next